EZZ Life Science Holdings Management
Management criteria checks 3/4
EZZ Life Science Holdings' CEO is Qizhou Qin, appointed in Oct 2021, has a tenure of 3.17 years. total yearly compensation is A$210.65K, comprised of 85.5% salary and 14.5% bonuses, including company stock and options. directly owns 26.94% of the company’s shares, worth A$36.19M. The average tenure of the management team and the board of directors is 3.2 years and 4.2 years respectively.
Key information
Qizhou Qin
Chief executive officer
AU$210.6k
Total compensation
| CEO salary percentage | 85.5% |
| CEO tenure | 3.2yrs |
| CEO ownership | 26.9% |
| Management average tenure | 3.2yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
EZZ Life Science Holdings Limited (ASX:EZZ) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
Nov 04
EZZ Life Science Holdings Limited's (ASX:EZZ) Shares Leap 41% Yet They're Still Not Telling The Full Story
Aug 28EZZ Life Science Holdings Limited (ASX:EZZ) Stock Catapults 29% Though Its Price And Business Still Lag The Market
Jun 05There's No Escaping EZZ Life Science Holdings Limited's (ASX:EZZ) Muted Earnings Despite A 28% Share Price Rise
Apr 02Here's Why We Think EZZ Life Science Holdings (ASX:EZZ) Is Well Worth Watching
Feb 09EZZ Life Science Holdings Limited's (ASX:EZZ) Share Price Is Matching Sentiment Around Its Earnings
Oct 18EZZ Life Science Holdings' (ASX:EZZ) Promising Earnings May Rest On Soft Foundations
Mar 06Calculating The Fair Value Of EZZ Life Science Holdings Limited (ASX:EZZ)
Nov 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$211k | AU$180k | AU$7m |
| Mar 31 2024 | n/a | n/a | AU$5m |
| Dec 31 2023 | n/a | n/a | AU$3m |
| Sep 30 2023 | n/a | n/a | AU$4m |
| Jun 30 2023 | AU$173k | AU$152k | AU$4m |
| Mar 31 2023 | n/a | n/a | AU$3m |
| Dec 31 2022 | n/a | n/a | AU$3m |
| Sep 30 2022 | n/a | n/a | AU$2m |
| Jun 30 2022 | AU$127k | AU$115k | AU$1m |
| Mar 31 2022 | n/a | n/a | AU$1m |
| Dec 31 2021 | n/a | n/a | AU$907k |
| Sep 30 2021 | n/a | n/a | AU$1m |
| Jun 30 2021 | AU$131k | AU$120k | AU$2m |
| Mar 31 2021 | n/a | n/a | AU$2m |
| Dec 31 2020 | n/a | n/a | AU$2m |
| Sep 30 2020 | n/a | n/a | AU$2m |
| Jun 30 2020 | AU$164k | AU$150k | AU$2m |
Compensation vs Market: Qizhou's total compensation ($USD131.74K) is below average for companies of similar size in the Australian market ($USD291.73K).
Compensation vs Earnings: Qizhou's compensation has increased by more than 20% in the past year.
CEO
Qizhou Qin
3.2yrs
Tenure
AU$210,645
Compensation
Mr. Mark Qin, is also known as Qizhou, serves as the Chief Operating Officer at EZZ Life Science Holdings Limited and serves as its Executive Director since September 1, 2019. He is Co-founder of EZZ Life...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-founder | 3.2yrs | AU$210.65k | 26.94% A$ 36.2m | |
| Chief Financial Officer | 3.2yrs | AU$151.34k | 0.021% A$ 28.5k | |
| Company Secretary | 4.4yrs | no data | no data |
3.2yrs
Average Tenure
Experienced Management: EZZ's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-founder | 5.3yrs | AU$210.65k | 26.94% A$ 36.2m | |
| Independent Non-Executive Director | 4.2yrs | AU$70.37k | 0.011% A$ 14.5k | |
| Independent Non-Executive Director | 4.2yrs | AU$85.68k | 0.056% A$ 75.7k | |
| Independent Non-Executive Chairperson | 3.1yrs | AU$100.37k | 0.097% A$ 130.9k |
4.2yrs
Average Tenure
Experienced Board: EZZ's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 02:54 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
EZZ Life Science Holdings Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Lodge Partners Pty Ltd. |
| Chris Kallos | MST Financial Services Pty Limited |